Biosergen, a clinical-stage biotech developing novel antifungal therapies, has appointed Mark Beveridge as Chief Financial Officer to steer its financial strategy. With over 15 years of expertise in financial management and biotech, Beveridge joins as the company advances its lead candidate, BSG005, toward global trials to combat life-threatening fungal infections.
Read the full interview with Mark Beveridge at biostock.se:
https://biostock.se/en/2025/07/biosergen-strengthens-executive-team-amid-clinical-momentum/
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/